DOCSLIB.ORG

A Potential Role in the D-Binding Protein (Gc-Globulin) to Elastase

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Potential Role in the D-Binding Protein (Gc-Globulin) to Elastase Elastase Controls the Binding of the Vitamin D-Binding Protein (Gc-Globulin) to Neutrophils: A Potential Role in the Regulation of C5a Co-Chemotactic Activity This information is current as of September 26, 2021. Stephen J. DiMartino, Anisha B. Shah, Glenda Trujillo and Richard R. Kew J Immunol 2001; 166:2688-2694; ; doi: 10.4049/jimmunol.166.4.2688 http://www.jimmunol.org/content/166/4/2688 Downloaded from References This article cites 64 articles, 19 of which you can access for free at: http://www.jimmunol.org/content/166/4/2688.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 26, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2001 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Elastase Controls the Binding of the Vitamin D-Binding Protein (Gc-Globulin) to Neutrophils: A Potential Role in the Regulation of C5a Co-Chemotactic Activity1 Stephen J. DiMartino, Anisha B. Shah, Glenda Trujillo, and Richard R. Kew2 The vitamin D-binding protein (DBP) binds to the plasma membranes of numerous cell types and mediates a diverse array of cellular functions. DBP bound to the surface of leukocytes serves as a co-chemotactic factor for C5a, significantly enhancing the chemotactic activity of pM concentrations of C5a. This study investigated the regulation of DBP binding to neutrophils as a possible key step in the process of chemotaxis enhancement to C5a. Using radioiodinated DBP as a probe, neutrophils released 70% of previously bound DBP into the extracellular media during a 60-min incubation at 37°C. This was suppressed by serine protease inhibitors (PMSF, Pefabloc SC), but not by metallo- or thiol-protease inhibitors. DBP shed from neutrophils had no Downloaded from detectable alteration in its m.w., suggesting that a serine protease probably cleaves the DBP binding site, releasing DBP in an unaltered form. Cells treated with PMSF accumulate DBP vs time with over 90% of the protein localized to the plasma membrane. Purified neutrophil plasma membranes were used to screen a panel of protease inhibitors for their ability to suppress shedding of the DBP binding site. Only inhibitors to neutrophil elastase prevented the loss of membrane DBP-binding capacity. Moreover, treatment of intact neutrophils with elastase inhibitors prevented the generation of C5a co-chemotactic activity from DBP. These results indicate that steady state binding of DBP is essential for co-chemotactic activity, and further suggest that neutrophil http://www.jimmunol.org/ elastase may play a critical role in the C5a co-chemotactic mechanism. The Journal of Immunology, 2001, 166: 2688–2694. omplement activation and cleavage of C5 generate the significantly enhance the chemotactic activity (i.e., co-chemotactic potent chemoattractants C5a, and its derivative, C5a des activity) of C5-derived peptides for human (11–16) and bovine C Arg. C5-derived peptides are considered to be among the neutrophils (17). DBP also has been shown to augment monocyte most physiologically important leukocyte chemotactic factors (1, and fibroblast chemotaxis to C5-derived peptides (18, 19). The 2). During the past several years, the use of molecular approaches chemotactic enhancing properties of DBP appear to be restricted to has substantially enhanced the knowledge about several major che- C5a/C5a des Arg because this protein cannot enhance the chemo- moattractants and their receptors (3–6). However, much less at- tactic activity of formylated peptides, IL-8, leukotriene B4,or by guest on September 26, 2021 tention has been paid to extracellular inhibitory and enhancing platelet-activating factor (11–17). Although DBP appears to be a factors that modulate chemoattractant function, several of which physiologically important regulator of leukocyte chemotactic ac- have been described over the last 25 years (7, 8). Identification of tivity for activated complement, the mechanism of chemotactic specific regulatory molecules and/or their mechanisms of action enhancement is not yet known. largely have remained obscure, although there are a couple of no- DBP is a multifunctional 56-kDa plasma protein that can bind table exceptions (9, 10). The vitamin D-binding protein (DBP),3 several diverse ligands (20, 21). In addition to functioning as a also known as Gc-globulin, is one protein that has been shown to co-chemotactic factor for C5-derived peptides, DBP functions to transport vitamin D sterols and acts as a scavenger protein to clear extracellular G-actin released from necrotic cells, and a deglyco- Department of Pathology, School of Medicine, State University of New York, Stony Brook, NY 11794 sylated form of DBP has been shown to be a potent macrophage and osteoclast-activating factor (22). Plasma-derived DBP also Received for publication August 16, 2000. Accepted for publication December 1, 2000. binds to the surface of many cell types including neutrophils (23– The costs of publication of this article were defrayed in part by the payment of page 25). DBP bound to the plasma membrane of neutrophils appears to charges. This article must therefore be hereby marked advertisement in accordance play an essential role in enhancing chemotaxis to C5-derived pep- with 18 U.S.C. Section 1734 solely to indicate this fact. tides (26). Recently, we have demonstrated that a cell surface 1 This investigation was supported in part by grants to R.R.K. from the Smokeless chondroitin sulfate proteoglycan serves as the DBP binding site on Tobacco Research Council (0548) and the Scleroderma Foundation (001099). S.J.D. was supported in part by a Medical Scientist Training Program Grant from the Na- neutrophils (27). Moreover, another recent report has shown that tional Institutes of Health. A.B.S. was supported in part by the M.D. with Distinction ␮ DBP binds with low affinity (Kd of 111 M) to megalin (600-kDa in Research Program, School of Medicine, State University of New York at Stony Brook. G.T. was supported by a W. Burghardt Turner Fellowship and a National multiligand clearance receptor) on the surface of renal proximal Institute of Health Training Grant (GM 08468). tubule cells (28). However, megalin is not expressed on neutro- 2 Address correspondence and reprint requests to Dr. Richard R. Kew, Department of phils or other cells of the myeloid lineage (29, 30). Identification Pathology, State University of New York, Stony Brook, NY 11794-8691. E-mail of cell surface DBP binding sites is a major step for our under- address: [email protected] standing of the C5a co-chemotactic mechanism. However, little is 3 Abbreviations used in this paper: DBP, vitamin D-binding protein; AAPA-CMK, known concerning the regulation of DBP binding to cells. N-methoxysuccinyl-ala-ala-pro-ala-chloromethyl ketone; AAPV-CMK, N-methoxy- succinyl-ala-ala-pro-val-chloromethyl ketone; E-64, trans-epoxysuccinyl-L-leucyl- Protease-mediated cleavage and shedding of plasma membrane amido-(4-guanidino)butane; FFR-CMK, D-phenylalanine-L-phenylalanine-L-arginine- macromolecules is a well-established negative regulatory mecha- chloromethyl ketone; FPR-CMK, D-phenylalanine-L-proline-L-arginine-chloromethyl ketone; 125I-DBP, 125I-labeled DBP; SLPI, secretory leukocyte protease inhibitor; nism (31). Neutrophils in particular employ cell surface proteases Z-GLF-CMK, carbobenzoxy-glycine-leucine-phenylalanine-chloromethyl ketone. to rapidly change their profile of cell surface macromolecules. Copyright © 2001 by The American Association of Immunologists 0022-1767/01/$02.00 The Journal of Immunology 2689 Neutrophil elastase, also known as human leukocyte elastase mM EDTA, 10 mM NaN3, as well as the following inhibitors added fresh (E.C.3.4.21.37), has been shown to cleave several CD Ags (CD14, immediately before lysis: 2 mM PMSF, 2 mM 1,10-phenanthroline, 0.5 CD16, CD43, CD44), releasing a soluble form into the extracel- mM E-64, 0.2 mM 3,4-dichloroisocoumarin, 0.1 mM leupeptin, and 0.1 mM pepstatin. Lysates were vortexed thoroughly until all particulate matter lular media (32, 33). Although the majority of neutrophil elastase was solubilized (usually 5–10 s) and then placed at 37°C for 60 min. The is stored in azurophil granules, several reports have demonstrated detergent-insoluble material was then pelleted by centrifuging the lysates active enzyme on the cell surface (34–37). An earlier report from in a microfuge for 10 min at 15,000 ϫ g at 4°C. our laboratory has shown that, at 37°C, neutrophils shed DBP from Chemotaxis assay the plasma membrane into the extracellular media (26). Moreover, the loss of DBP from the cell surface is correlated temporally Cell movement was quantitated using a 48-well microchemotaxis chamber with the decay in C5a co-chemotactic activity (26). These results (Neuroprobe, Cabin John, MD) and 5-␮m pore-size cellulose nitrate filters suggested that either DBP or its binding site is proteolytically pro- (Toyo, purchased from Neuroprobe), as previously described (26). cessed by neutrophils. The goal of the present study was to char- PAGE and autoradiography acterize the regulation of DBP binding to human neutrophils. The results demonstrate that elastase is needed for steady state binding Samples were separated by PAGE in the presence of SDS (SDS-PAGE) using the discontinuous buffer system described by Laemmli (39).
Load more

Recommended publications
  • Effects of Glycosylation on the Enzymatic Activity and Mechanisms of Proteases
    International Journal of Molecular Sciences Review Effects of Glycosylation on the Enzymatic Activity and Mechanisms of Proteases Peter Goettig Structural Biology Group, Faculty of Molecular Biology, University of Salzburg, Billrothstrasse 11, 5020 Salzburg, Austria; [email protected]; Tel.: +43-662-8044-7283; Fax: +43-662-8044-7209 Academic Editor: Cheorl-Ho Kim Received: 30 July 2016; Accepted: 10 November 2016; Published: 25 November 2016 Abstract: Posttranslational modifications are an important feature of most proteases in higher organisms, such as the conversion of inactive zymogens into active proteases. To date, little information is available on the role of glycosylation and functional implications for secreted proteases. Besides a stabilizing effect and protection against proteolysis, several proteases show a significant influence of glycosylation on the catalytic activity. Glycans can alter the substrate recognition, the specificity and binding affinity, as well as the turnover rates. However, there is currently no known general pattern, since glycosylation can have both stimulating and inhibiting effects on activity. Thus, a comparative analysis of individual cases with sufficient enzyme kinetic and structural data is a first approach to describe mechanistic principles that govern the effects of glycosylation on the function of proteases. The understanding of glycan functions becomes highly significant in proteomic and glycomic studies, which demonstrated that cancer-associated proteases, such as kallikrein-related peptidase 3, exhibit strongly altered glycosylation patterns in pathological cases. Such findings can contribute to a variety of future biomedical applications. Keywords: secreted protease; sequon; N-glycosylation; O-glycosylation; core glycan; enzyme kinetics; substrate recognition; flexible loops; Michaelis constant; turnover number 1.
    [Show full text]
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • Contents Supplemental Table 1
    Supplementary material Open Heart SUPPLEMENTAL MATERIAL TO “EXPLORATION OF PATHOPHYSIOLOGICAL PATHWAYS FOR INCIDENT ATRIAL FIBRILLATION – THE MALMÖ PREVENTIVE PROJECT” John Molvin, Amra Jujic, Olle Melander, Manan Pareek, Lennart Råstam, Ulf Lindblad, Bledar Daka, Margrét Leósdóttir, Peter M. Nilsson, Michael H. Olsen & Martin Magnusson Contents Supplemental table 1. Unadjusted Cox regression analyses examining all 92 proteins relation to incident atrial fibrillation ................................................................................... 2-3 List of abbreviations……………………………………………………………………………………………………………4 Molvin J, et al. Open Heart 2020; 7:e001190. doi: 10.1136/openhrt-2019-001190 Supplementary material Open Heart Supplemental table 1. Unadjusted Cox regression analyses examining all 92 proteins relation to incident atrial fibrillation Protein Hazard ratio (95% confidence interval) p-value PON3 0.80 (0.72-0.89) 7.3x10-5 IGFBP2 4.47 (1.42-14-1) 0.011 PAI 1.44 (0.65-3.18) 0.371 CTSD 2.45 (1.13-5.30) 0.023 FABP4 1.27 (1.13-1.44) 8.6x10-5 CD163 5.25 (1.14-24.1) 0.033 GAL4 1.30 (1.15-1.47) 3.5x10-5 LDL-receptor 0.81 (0.39-1.69) 0.582 IL1RT2 0.75 (0.24-2.34) 0.614 t-PA 2.75 (1.21-6.27) 0.016 SELE 0.99 (0.51-1.90) 0.969 CTSZ 2.97 (1.00-8.78) 0.050 GDF15 1.41 (1.25-1.59) 9.7x10-9 CSTB 3.75 (1.58-8.92) 0.003 MPO 4.48 (1.73-11.7) 0.002 PCSK9 1.18 (0.73-1.93) 0.501 IGFBP1 2.48 (1.42-4.35) 0.001 RARRES2 64.3 (1.87-2220.8) 0.021 ITGB2 1.01 (0.31-3.29) 0.990 CCL15 3.58 (0.96-13.3) 0.057 SCGB3A2 0.97 (0.71-1.32) 0.839 CHI3L1 1.26 (1.12-1.43)
    [Show full text]
  • Proteome Profiler Human Protease Array Kit
    Proteome ProfilerTM Array Human Protease Array Kit Catalog Number ARY021 For the parallel determination of the relative levels of selected human proteases. This package insert must be read in its entirety before using this product. For research use only. Not for use in diagnostic procedures. TABLE OF CONTENTS SECTION PAGE INTRODUCTION .....................................................................................................................................................................1 PRINCIPLE OF THE ASSAY ...................................................................................................................................................1 TECHNICAL HINTS .................................................................................................................................................................1 MATERIALS PROVIDED & STORAGE CONDITIONS ...................................................................................................2 OTHER SUPPLIES REQUIRED .............................................................................................................................................3 SUPPLIES REQUIRED FOR CELL LYSATE SAMPLES ...................................................................................................3 SUPPLIES REQUIRED FOR TISSUE LYSATE SAMPLES ...............................................................................................3 SAMPLE COLLECTION & STORAGE .................................................................................................................................4
    [Show full text]
  • Design of Ultrasensitive Probes for Human Neutrophil Elastase Through Hybrid Combinatorial Substrate Library Profiling
    Design of ultrasensitive probes for human neutrophil elastase through hybrid combinatorial substrate library profiling Paulina Kasperkiewicza, Marcin Porebaa, Scott J. Snipasb, Heather Parkerc, Christine C. Winterbournc, Guy S. Salvesenb,c,1, and Marcin Draga,b,1 aDivision of Bioorganic Chemistry, Faculty of Chemistry, Wroclaw University of Technology, Wroclaw 50-370, Poland; bProgram in Cell Death and Survival Networks, Sanford-Burnham Medical Research Institute, La Jolla, CA 92024; and cCentre for Free Radical Research, Department of Pathology, University of Otago Christchurch, Christchurch 8140, New Zealand Edited* by Vishva M. Dixit, Genentech, San Francisco, CA, and approved January 15, 2014 (received for review October 1, 2013) The exploration of protease substrate specificity is generally possibilities. Here we demonstrate a general approach for the syn- restricted to naturally occurring amino acids, limiting the degree of thesis of combinatorial libraries containing unnatural amino acids, conformational space that can be surveyed. We substantially with subsequent screening and analysis of large sublibraries. We enhanced this by incorporating 102 unnatural amino acids to term this approach the Hybrid Combinatorial Substrate Library explore the S1–S4 pockets of human neutrophil elastase. This ap- (HyCoSuL). We demonstrate the utility of this approach in the proach provides hybrid natural and unnatural amino acid sequen- design of a highly selective substrate and activity-based probe. ces, and thus we termed it the Hybrid Combinatorial Substrate As a target protease, we selected human neutrophil elastase Library. Library results were validated by the synthesis of individ- (EC 3.4.21.37) (NE), a serine protease restricted to neutrophil ual tetrapeptide substrates, with the optimal substrate demon- azurophil granules (14).
    [Show full text]
  • Fibrinolysis Influences SARS-Cov-2 Infection in Ciliated Cells
    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.07.425801; this version posted January 8, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Fibrinolysis influences SARS-CoV-2 infection in ciliated cells 2 3 Yapeng Hou1, Yan Ding1, Hongguang Nie1, *, Hong-Long Ji2 4 5 1Department of Stem Cells and Regenerative Medicine, College of Basic Medical Science, China Medical 6 University, Shenyang, Liaoning 110122, China. 2Department of Cellular and Molecular Biology, University 7 of Texas Health Science Center at Tyler, Tyler, TX 75708, USA. 8 9 *Address correspondence to [email protected] 10 11 bioRxiv preprint doi: https://doi.org/10.1101/2021.01.07.425801; this version posted January 8, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 12 Abstract 13 Rapid spread of COVID-19 has caused an unprecedented pandemic worldwide, and an inserted furin site 14 in SARS-CoV-2 spike protein (S) may account for increased transmissibility. Plasmin, and other host 15 proteases, may cleave the furin site of SARS-CoV-2 S protein and subunits of epithelial sodium channels ( 16 ENaC), resulting in an increment in virus infectivity and channel activity. As for the importance of ENaC in 17 the regulation of airway surface and alveolar fluid homeostasis, whether SARS-CoV-2 will share and 18 strengthen the cleavage network with ENaC proteins at the single-cell level is urgently worthy of consideration.
    [Show full text]
  • Monoacylglycerol Lipase Inhibition in Human and Rodent Systems Supports Clinical Evaluation of Endocannabinoid Modulators S
    Supplemental material to this article can be found at: http://jpet.aspetjournals.org/content/suppl/2018/10/10/jpet.118.252296.DC1 1521-0103/367/3/494–508$35.00 https://doi.org/10.1124/jpet.118.252296 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 367:494–508, December 2018 Copyright ª 2018 The Author(s). This is an open access article distributed under the CC BY Attribution 4.0 International license. Monoacylglycerol Lipase Inhibition in Human and Rodent Systems Supports Clinical Evaluation of Endocannabinoid Modulators s Jason R. Clapper, Cassandra L. Henry, Micah J. Niphakis, Anna M. Knize, Aundrea R. Coppola, Gabriel M. Simon, Nhi Ngo, Rachel A. Herbst, Dylan M. Herbst, Alex W. Reed, Justin S. Cisar, Olivia D. Weber, Andreu Viader, Jessica P. Alexander, Mark L. Cunningham, Todd K. Jones, Iain P. Fraser, Cheryl A. Grice, R. Alan B. Ezekowitz, ’ Gary P. O Neill, and Jacqueline L. Blankman Downloaded from Abide Therapeutics, San Diego, California Received July 26, 2018; accepted October 5, 2018 ABSTRACT Monoacylglycerol lipase (MGLL) is the primary degradative whether selective MGLL inhibition would affect prostanoid pro- jpet.aspetjournals.org enzyme for the endocannabinoid 2-arachidonoylglycerol (2- duction in several human assays known to be sensitive AG). The first MGLL inhibitors have recently entered clinical to cyclooxygenase inhibitors. ABD-1970 robustly elevated brain development for the treatment of neurologic disorders. To 2-AG content and displayed antinociceptive and antipru- support this clinical path, we report the pharmacological ritic activity in a battery of rodent models (ED50 values of characterization of the highly potent and selective MGLL inhibitor 1–2 mg/kg).
    [Show full text]
  • Measurement of Free and Membrane-Bound Cathepsin G In
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Repositório Institucional UNIFESP Biochem. J. (2002) 366, 965–970 (Printed in Great Britain) 965 Measurement of free and membrane-bound cathepsin G in human neutrophils using new sensitive fluorogenic substrates Sylvie ATTUCCI*, Brice KORKMAZ*, Luiz JULIANO†, Eric HAZOUARD*, Catherine GIRARDIN*, Miche' le BRILLARD-BOURDET*, Sophie RE; HAULT*, Philippe ANTHONIOZ* and Francis GAUTHIER*1 *INSERM EMI-U 00-10 ‘‘Prote! ases et Vectorisation’’, Laboratory of Enzymology and Protein Chemistry, University Franc: ois Rabelais, 2bis Bd Tonnelle! , 37032 TOURS Cedex, France, and †Departamento de Biofı!sica, Escola Paulista de Medicina, Universidade Federal de Sa4 o Paulo, Rua Tre# s de Maio, 100, Sa4 o Paulo 04044-020, Brazil Activated human polymorphonuclear neutrophils at inflamma- sin G but not by neutrophil elastase or proteinase 3, with \ & −" : −" tory sites release the chymotrypsin-like protease cathepsin G, specificity constants (kcat Km) in the 10 M s range. They together with elastase and proteinase 3 (myeloblastin), from their can be used to measure subnanomolar concentrations of free azurophil granules. The low activity of cathepsin G on synthetic enzyme in itro and at the surface of neutrophils purified from substrates seriously impairs studies designed to clarify its role in fresh human blood. Purified neutrophils express 0.02–0.7 pg of tissue inflammation. We have solved this problem by producing cathepsin G\cell (n l 15) at their surface. This means that about new peptide substrates with intramolecularly quenched fluor- 10% purified cells may be enough to record cathepsin G activity escence.
    [Show full text]
  • The Immune System and Kidney Disease: Basic Concepts and Clinical Implications
    REVIEWS The immune system and kidney disease: basic concepts and clinical implications Christian Kurts1, Ulf Panzer2, Hans-Joachim Anders3 and Andrew J. Rees4 Abstract | The kidneys are frequently targeted by pathogenic immune responses against renal autoantigens or by local manifestations of systemic autoimmunity. Recent studies in rodent models and humans have uncovered several underlying mechanisms that can be used to explain the previously enigmatic immunopathology of many kidney diseases. These mechanisms include kidney-specific damage-associated molecular patterns that cause sterile inflammation, the crosstalk between renal dendritic cells and T cells, the development of kidney-targeting autoantibodies and molecular mimicry with microbial pathogens. Conversely, kidney failure affects general immunity, causing intestinal barrier dysfunction, systemic inflammation and immunodeficiency that contribute to the morbidity and mortality of patients with kidney disease. In this Review, we summarize the recent findings regarding the interactions between the kidneys and the immune system. Considerable progress has been made both in under- role of the cellular immune responses that drive renal 1Institutes of Molecular standing the basic immune mechanisms of kidney disease. Moreover, we summarize recent discoveries Medicine and Experimental disease and in translating these findings to clinical about complement- and antibody-mediated nephritis, Immunology (IMMEI), therapies. Sophisticated animal studies combined and we discuss kidney pathologies that are mediated Rheinische Friedrich- with the analysis of clinical samples have led to a pre- by renal autoantigen-specific antibodies, especially those Wilhelms-Universität, cise knowledge of the autoimmune targets and of the that are induced by crossreactive microorganism-specific Sigmund-Freud-Str. 25, 53105 Bonn, Germany. mechanisms responsible for kidney injury.
    [Show full text]
  • Proteinase 3; a Potential Target in Chronic Obstructive Pulmonary Disease and Other Chronic Inflammatory Diseases Helena Crisford1,3* , Elizabeth Sapey1 and Robert A
    Crisford et al. Respiratory Research (2018) 19:180 https://doi.org/10.1186/s12931-018-0883-z REVIEW Open Access Proteinase 3; a potential target in chronic obstructive pulmonary disease and other chronic inflammatory diseases Helena Crisford1,3* , Elizabeth Sapey1 and Robert A. Stockley2 Abstract Chronic Obstructive Pulmonary Disease (COPD) is a common, multifactorial lung disease which results in significant impairment of patients’ health and a large impact on society and health care burden. It is believed to be the result of prolonged, destructive neutrophilic inflammation which results in progressive damage to lung structures. During this process, large quantities of neutrophil serine proteinases (NSPs) are released which initiate the damage and contribute towards driving a persistent inflammatory state. Neutrophil elastase has long been considered the key NSP involved in the pathophysiology of COPD. However, in recent years, a significant role for Proteinase 3 (PR3) in disease development has emerged, both in COPD and other chronic inflammatory conditions. Therefore, there is a need to investigate the importance of PR3 in disease development and hence its potential as a therapeutic target. Research into PR3 has largely been confined to its role as an autoantigen, but PR3 is involved in triggering inflammatory pathways, disrupting cellular signalling, degrading key structural proteins, and pathogen response. This review summarises what is presently known about PR3, explores its involvement particularly in the development of COPD, and
    [Show full text]
  • Sequence and Evolutionary Analysis of the Human Trypsin Subfamily of Serine Peptidases
    Biochimica et Biophysica Acta 1698 (2004) 77–86 www.bba-direct.com Sequence and evolutionary analysis of the human trypsin subfamily of serine peptidases George M. Yousefa,b, Marc B. Elliotta, Ari D. Kopolovica, Eman Serryc, Eleftherios P. Diamandisa,b,* a Department of Pathology and Laboratory Medicine, Division of Clinical Biochemistry, Mount Sinai Hospital, 600 University Avenue, Toronto, ON, Canada M5G 1X5 b Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada M5G 1L5 c Faculty of Medicine, Department of Medical Biochemistry, Menoufiya University, Egypt Received 3 June 2003; received in revised form 1 October 2003; accepted 27 October 2003 Abstract Serine peptidases (SP) are peptidases with a uniquely activated serine residue in the substrate-binding site. SP can be classified into clans with distinct evolutionary histories and each clan further subdivided into families. We analyzed 79 proteins representing the S1A subfamily of human SP, obtained from different databases. Multiple alignment identified 87 highly conserved amino acid residues. In most cases of substitution, a residue of similar character was inserted, implying that the overall character of the local region was conserved. We also identified several conserved protein motifs. 7–13 cysteine positions, potentially forming disulfide bridges, were also found to be conserved. Most members are secreted as inactive (pro) forms with a trypsin-like cleavage site for activation. Substrate specificity was predicted to be trypsin-like for most members, with few chymotrypsin-like proteins. Phylogenetic analysis enabled us to classify members of the S1A subfamily into structurally related groups; this might also help to functionally sort members of this subfamily and give an idea about their possible functions.
    [Show full text]
  • Molecular Imaging of Breast Cancer
    MOLECULAR IMAGING OF BREAST CANCER USING PARACEST MRI by BYUNGHEE YOO Submitted in partial fulfillment of the requirements For the degree of Doctor of Philosophy Thesis Advisor: Prof. Mark D. Pagel, Ph.D. Department of Biomedical Engineering CASE WESTERN RESERVE UNIVERSITY August, 2007 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the dissertation of ________________BYUNGHEE YOO_____________________ candidate for the Doctor of Philosophy degree *. (signed) Mark D. Pagel, Ph.D. (chair of the committee) Raymon F. Muzic, Ph.D. Suneel S. Apte, Ph.D. Xin Yu, Sc.D. (date) June 15, 2007 *We also certify that written approval has been obtained for any proprietary material contained therein. Copyright © 2006 by Byunghee Yoo All rights reserved iii DEDICATION To my family and my mentors iv Table of Contents Title page …..……………………………………………………………..…………. …. i Committee signature …………..…………………………………………..………... …. ii Copyright……………………………………………………………………………. … iii Dedication ………………………………………………………………………..…. ….iv Table of Contents..………………………………………………………….….……. …..1 List of Tables..……………………………………………………………….…...…. …..4 List of Schemes…………………………………………………………….….….…. …..5 List of Figures……………………………………………………………….….….... …..6 Preface……………………………………………………………………….….….... …..8 Acknowledgements……………………………………………………..….………... .…10 List of Abbreviations…………………………………………………………………….12 Abstract……………………………………………………………….……………... .....13 Chapter I. Introduction………………………………………………………………… ..15 1. Breast cancer and molecular MR imaging…………………………………….
    [Show full text]